What’s New: Natural and Synthetic Antibacterials and/or Agents with Multiple Activities? 3rd Volume

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1329

Special Issue Editor

Special Issue Information

Dear Colleagues,

We have published two successful volumes of the Special Issue “What’s New: Natural and Synthetic Antibacterials and/or Agents with Multiple Activities?”, and this encourages us to open a third volume focused on the same topic.

As a continuation of the Special Issues, the third volume will welcome the study and biological evaluation of new natural and synthetic compounds, highlighting antibacterial activity along with other activities, such as those that are antitumoral, antiviral, anti-inflammatory, etc.

Prof. Dr. Maria Stefania Sinicropi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural antibacterials
  • synthetic antibacterials
  • antitumorals
  • antivirals
  • antioxidants
  • antifungals
  • anti-inflammatory

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1372 KiB  
Article
Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents
by Alexia Barbarossa, Jessica Ceramella, Alessia Carocci, Domenico Iacopetta, Antonio Rosato, Francesco Limongelli, Antonio Carrieri, Daniela Bonofiglio and Maria Stefania Sinicropi
Antibiotics 2023, 12(12), 1651; https://doi.org/10.3390/antibiotics12121651 - 23 Nov 2023
Cited by 1 | Viewed by 1136
Abstract
The benzothiazole nucleus is a major heterocyclic scaffold whose therapeutic potential has been thoroughly explored due to its structural simplicity and ease of synthesis. In fact, several benzothiazole derivatives have been synthesized over time, demonstrating numerous pharmacological properties such as anticancer, antimicrobial, anti-inflammatory, [...] Read more.
The benzothiazole nucleus is a major heterocyclic scaffold whose therapeutic potential has been thoroughly explored due to its structural simplicity and ease of synthesis. In fact, several benzothiazole derivatives have been synthesized over time, demonstrating numerous pharmacological properties such as anticancer, antimicrobial, anti-inflammatory, and antioxidant activities. Herein, we propose a new series of benzothiazole-phthalimide hybrids obtained by linking the phthalimide moiety to differently substituted benzothiazole nuclei through the N atom. These compounds have been screened for their anticancer properties against two human breast cancer cell lines. Furthermore, we delved into the mechanism of action of the most active hybrid, compound 3h, by assessing its capability to damage the nuclear DNA, trigger the apoptotic process in the high metastatic MDA-MB-231 cells, and prevent cellular migration. Moreover, in view of the documented antimicrobial activities of the two scaffolds involved, we explored the antibacterial and antifungal effects of the studied compounds by means of the broth microdilution method. Among the studied compounds, 3h showed the highest antimicrobial activity, both against gram-positive and gram-negative bacterial strains belonging to the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and against fungal strains of the Candida species with MICs values ranging from 16 to 32 µg/mL. Full article
Show Figures

Graphical abstract

Back to TopTop